391 pharmaceutical companies posted transcripts for the first half of the year, 18 gross profit margins exceeded 90%

Pharmaceutical Network News, September 1 As of now, a total of 391 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021, and more than 70% of companies' performance (revenue, net profit) has both increased
.
Among them, 20 companies have a revenue of more than 10 billion yuan, Shanghai Pharmaceuticals has broken through the 100 billion yuan mark, ranking first, Jointown, Baiyunshan, etc.
have also reached new highs; 13 companies such as Zhifei Bio, Mindray Medical, and Hengrui Pharmaceutical have net The profit exceeded 2 billion yuan; the gross profit margin of 18 companies including Ellis, Biotech, and Wuwu Biotech exceeded 90%
.
In addition, 37 companies lost money, of which 26 lost less than 100 million yuan
.
It is worth mentioning that due to the impact of the epidemic in the first half of last year, the performance of many companies has declined, especially in the first quarter, where more than 50% of the companies’ performance doubled.
Under last year’s low base, companies have gradually returned to normal operations this year.
Better performance is the general consensus of the market
.
Net profit TOP10 : Zhifei, Mindray, Hengrui.
.
.
more than 2 billionin the first half of 2021, the net profit of pharmaceutical companies TOP10 (unit: 100 million yuan) From the point of view of net profit, there are 13 pharmaceutical companies in the first half of this year with a scale of over 2 billion yuan Among them, Ingram Medical and Zhifei Biotech exceeded the 5 billion mark, and Mindray Medical, Shanghai Pharmaceuticals, Oriental Biotech, WuXi AppTec all reached new highs
.
In the same period of 2020, there are only 5 companies with a net profit of more than 2 billion yuan, namely Mindray Medical, Hengrui Pharmaceutical, Yunnan Baiyao, Shanghai Pharmaceutical and Xinhecheng
.
On August 30, Zhifei Biological disclosed the 2021 semi-annual report, with a net profit of 5.
491 billion yuan, a year-on-year increase of 264.
94%, which has far exceeded the 2020 full-year net profit of 3.
301 billion yuan
.
As of the first half of the year, Zhifei Bio has 10 products on sale, and 1 product is used for emergency use, including vaccine products to prevent infectious diseases such as meningitis, cervical cancer, and pneumonia, covering those that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infection.
Medicines, covering people including infants , young children , adolescents, and adults
.
Prior to this (August 27), Zhifei Biological issued an announcement stating that the recombinant new coronavirus vaccine (CHO cell) developed by the wholly-owned subsidiary Anhui Zhifei Longkoma Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences has obtained Phase III clinical trials.
The key data of the experiment, preliminary analysis results show: the protective effect of Alpha mutant strain is 92.
93%; the protective effect of Delta mutant strain is 77.
54%
.
Brokerage analysis pointed out that the disclosure of key clinical data of the new crown vaccine phase III shows that the company is expected to gradually open up overseas markets while meeting domestic production capacity, which will bring a greater increase in the company's profit contribution
.
As a leading CRO company, WuXi AppTec has attracted much attention in the industry
.
In the first half of this year, WuXi AppTec's net profit hit a new high, surpassing 2 billion yuan for the first time, a year-on-year increase of 55.
79%
.
WuXi AppTec stated that in the first half of last year, the company's low operating efficiency has been fully restored due to the impact of the new crown epidemic, operating efficiency has maintained a good level, capacity utilization and operating efficiency have been continuously improved, and operating profit has increased significantly; in addition, investment income and fairness The value change income totaled 1.
025 billion yuan
.
  　　Gross profit margin TOP10 :   　　Pharmaceutical companies on the Science and Technology Innovation Board won the "One Brother" throne.
In the first half of 2021, the gross profit margin of pharmaceutical companies is TOP10.
From the perspective of gross profit margin, 18 pharmaceutical companies have gross profit margins of more than 90%
.
Iris from the Science and Technology Innovation Board won the "Big Brother" throne; Biotech followed closely behind with its strong growth rate, and Wu Biotech and Yiqiao Shenzhou also exceeded 95%
.
It is worth noting that in the TOP10, except for Wuwu Biotechnology, Yiqiao Shenzhou, Amic and Betta Pharmaceuticals, the other six are all companies from the science and technology innovation board, while there were only four in the same period last year.
This year, Kangxi Novo Sanyou Medical fell out of the top ten
.
In December last year, Iris officially landed on the Science and Technology Innovation Board, and its gross profit rate in the first half of this year was as high as 98.
70%, winning the "first brother" throne. .
It is understood that Alis is an innovative drug company focusing on the field of tumor treatment.
Its core product, national class 1 new drug vometinib, was approved in March and started to go on sale.
The company has established a marketing team of more than 300 people covering the country.
Nearly 800 hospitals in 30 provinces and cities, and about 250 DTP pharmacies, fully ensure the availability of vometinib for lung cancer patients
.
In addition, the company’s new drug projects for KRAS G12C inhibitors, KRAS G12D inhibitors, fourth-generation EGFR TKI, RET inhibitors and SOS1 inhibitors are all independently developed products, currently in the preclinical research stage, and plan to submit INDs in 2022-2024 Apply
.
Biotech's gross profit margin has steadily increased since its listing, from 86.
24% in the first half of 2020 to 96.
33% in the first half of 2021
.
As of the first half of this year, the company has one product (Adalimumab Injection (Galler)) on the market, which is the first adalimumab biosimilar drug approved for marketing in China
.
There are 20 main products under research, of which 2 products have been submitted for marketing applications, 3 products are in the phase III clinical research phase, 2 products are in the phase II clinical research phase, 6 products are in the phase I clinical research phase, and more This drug under research is in the pre-clinical research stage.
While enriching the company's product pipeline, it also lays the foundation for performance growth
.
A few days ago, Biotech and Hikma signed a licensing and commercialization agreement to license the company’s exclusive commercialization rights of BAT2206 (usnumab) injection in the US market to Hikma for a fee.
The total amount of down payment and milestone payment Up to US$150 million, it is expected to have a positive impact on the company’s future performance and help improve profitability
.
In the first half of the year, our revenue and net profit both rose by more than 30%, with revenue of 348 million yuan, net profit of 147 million yuan, and gross profit margin of 95.
66%.
The leading product "Dust Mite Drops" is the company's main source of revenue.
The sales revenue of this product largely determines the company's profitability
.
Regarding the relatively concentrated risk of leading products, Wu Biotech stated that the company’s new product "Artemisia annua pollen allergen sublingual drops" was approved in January this year, but it will take some time for the product to be sold on a large scale.
The promotion of new products promoted large-scale sales
.
In August of this year, Zhejiang Wowu Tage Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of Wuwu Biotechnology, completed the acquisition of a part of the equity of Shanghai Kaiyi Pharmaceutical and increased its capital, and Shanghai Kaiyi Pharmaceutical became its associate company
.
It is understood that the main business of Shanghai Kaiyi Medicine is to develop a new type of bronchodilator for patients with asthma and chronic obstructive pulmonary disease (the active ingredient is Kuding Saponin A isolated from Kudingcha)
.
The equity transfer and capital increase will help Wuwu Bio to further improve the "symptomatic + to cause" allergic disease drug treatment plan, covering diseases from allergic rhinitis and asthma to chronic obstructive pulmonary disease, forming an industry with the company Synergy
.
  　　Revenue TOP10: Shanghai Pharmaceuticals breaks through 100 billion, Jointown, Baiyunshan.
.
.
  　　 Set a new high in the first half of 2021 pharmaceutical companies revenue TOP10 (unit: 100 million yuan) From the perspective of revenue, Shanghai Pharmaceuticals, Jointown, Baiyunshan, Sinopharm All 20 companies including Accord have exceeded 10 billion yuan in scale
.
Among them, Shanghai Pharmaceuticals broke the 100 billion yuan mark, ranking first; Jointown and Baiyunshan also reached new highs
.
In the same period of 2020, there are 16 companies with revenues exceeding 10 billion yuan
.
On August 31, Shanghai Pharmaceuticals released the 2021 semi-annual report, operating revenue of 105.
2 billion yuan, a year-on-year increase of 20.
73%
.
The revenue of the pharmaceutical industry was 12.
602 billion yuan, a year-on-year increase of 7.
94%; the pharmaceutical business revenue was 92.
635 billion yuan, a year-on-year increase of 22.
71%
.
Shanghai Pharmaceuticals pointed out in the semi-annual report that the economy continued to recover steadily in the first half of the year, market demand continued to rebound, economic development was stable and positive, and the company maintained a good operating situation
.
In the pharmaceutical industry, the sales revenue of 60 key products increased by 11.
94% year-on-year, and the sales revenue of the top five key products with year-on-year growth doubled from the same period last year; the sales revenue of the Chinese medicine sector increased by 18% year-on-year
.
In terms of pharmaceutical commerce, it has consolidated its leading position in imports and actively expanded its innovative business.
The pharmaceutical commercial network covers 24 provinces and cities across the country, creating a modern pharmaceutical distribution system with a high degree of intensive and informatization
.
Jointown's revenue reached a new high in the first half of this year, breaking the scale of 60 billion yuan, an increase of 20.
70% year-on-year
.
Regarding the rapid growth of performance, Jointown said that on the one hand, the commercial distribution business strengthens the strategic cooperation of core distribution and top 100 chain stores, and continues to promote core e-commerce projects; on the other hand, the general agency general sales and self-produced business seize the good business opportunities of expansion and actively Introduce and vigorously promote high-quality general agent general sales products and self-produced products of the pharmaceutical industry, and optimize product structure and marketing strategies
.
A-share pharmaceutical companies’ performance in the first half of 2021.
Source: Oriental Fortune.
com
.
Announcements of listed companies.
Please correct me if there are any errors or omissions .